Modulators of sphingolipid metabolism reduce lung inflammation

American Journal of Respiratory Cell and Molecular Biology

Volumn 45, Issue 4, 2011, Pages 825-833

  Dechecchi, Maria Cristina ^a   Nicolis, Elena ^a   Mazzi, Paola ^b   Cioffi, Federica ^b   Bezzerri, Valentino ^a   Lampronti, Ilaria ^c   Huang, Song ^d   Wiszniewski, Ludovic ^d   Gambari, Roberto ^c   Scupoli, Maria Teresa ^b   Berton, Giorgio ^b   Cabrini, Giulio ^a  

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c UNIVERSITY OF FERRARA   (Italy)

^d Epithelix   (Switzerland)

Author keywords

Ceramide; Chemotaxis; Cystic fibrosis; Inflammation; Primary respiratory cells

Indexed keywords

AMITRIPTYLINE; BETA DEFENSIN 4; CERAMIDE; CHEMOKINE; CXCL3 CHEMOKINE; GRANULOCYTE CHEMOTACTIC PEPTIDE 2; GROWTH REGULATED PROTEIN ALPHA; GROWTH REGULATED PROTEIN BETA; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; MESSENGER RNA; MIGLUSTAT; NUCLEAR FACTOR; NUCLEAR FACTOR KB1; SPHINGOLIPID; TOLL LIKE RECEPTOR 2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BRONCHUS MUCOSA; CYSTIC FIBROSIS; DRUG EFFECT; HOST PATHOGEN INTERACTION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNITY; INNATE IMMUNITY; KERATINOCYTE; LIPID METABOLISM; LIPID STORAGE; MOUSE; NEUTROPHIL COUNT; NONHUMAN; PROTEIN EXPRESSION; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RESPIRATORY EPITHELIUM;

1-DEOXYNOJIRIMYCIN; AMITRIPTYLINE; ANIMALS; ANTI-INFLAMMATORY AGENTS; CELL LINE; CERAMIDES; DISEASE MODELS, ANIMAL; EPITHELIAL CELLS; GENE EXPRESSION REGULATION; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY, INNATE; INFLAMMATION MEDIATORS; INTERLEUKIN-8; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED C57BL; NEUTROPHIL INFILTRATION; PNEUMONIA; PSEUDOMONAS AERUGINOSA; RESPIRATORY MUCOSA;

MUS; PSEUDOMONAS AERUGINOSA;

EID: 80053620018     PISSN: 10441549     EISSN: None     Source Type: Journal    
DOI: 10.1165/rcmb.2010-0457OC     Document Type: Article

References (47)

1. Welsh JM, Ramsey BW, Accurso F, Cutting GR. Cystic fibrosis. In: Scriver CR, Beaudet AL, SlyWS, Valle D, editors. The metabolic and molecular bases of inherited diseases. New York: McGraw-Hill; 2001:5121-5189.
2. Mogayzel PJ, Flume PA. Update in cystic fibrosis 2009. Am J Respir Cell Mol Biol 2010;181:539-544.
3. Döring G, Worlitzsch D. Inflammation in cystic fibrosis and its management. Paediatr Respir Rev 2000;1:101-106.
4. Koehler DR, Downey GP, Sweezey NB, Tanswell AK, Hu J. Lung inflammation as a therapeutic target in cystic fibrosis. Am J Respir Cell Mol Biol 2004;31:377-381. (Pubitemid 39330947)
5. Konstan MW, Doring G, Lands LC, Hilliard KA, Koker P, Bhattacharya S, Staab A, Hamilton AL. Results of a Phase II clinical trial of BIIL284 BS for the treatment of CF lung disease. Pediatr Pulmonol Suppl 2005;28:125-126.
6. Lahiri S, Futerman AH. The metabolism and function of sphingolipids and glycoshingolipids. Cell Mol Life Sci 2007;64:2270-2284.
7. Uhlig S, Gulbins E. Sphingolipids in the lungs. Am J Respir Crit Care Med 2008;178:1100-1114.
8. Hannun YA, Obeid LM. Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol 2008;9:139-150. (Pubitemid 351158911)
9. Grassmé H, Jendrossek V, Riehle A, von Kürthy G, Berger J, Schwarz H, Weller M, Kolesnick R, Gulbins E. Host defense against Pseudomonas aeruginosa requires ceramide-rich membrane rafts. Nat Med 2003;9:322-330. (Pubitemid 36362788)
10. Teichgraber V, UlrichM, Endlich N, Riethmüller J, Wilker B, De Oliveira- Munding CC, van Heeckeren AM, Barr ML, von Kürthy G, Schmid KW, et al. Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis. Nat Med 2008;14: 382-391. (Pubitemid 351499396)
11. Guilbault C, De Sanctis JB, Wojewodka G, Saeed Z, Lachance C, Skinner TA, Vilela RM, Kubow S, Lands LC, Hajduch M, et al. Fenretinide corrects newly found ceramide deficiency in cystic fibrosis. Am J Respir Cell Mol Biol 2008;38:47-56.
12. Hicks AA, Pramstaller PP, Johansson A, Vitart V, Rudan I, Ugocsai P, Aulchenko Y, Franklin CS, Liebisch G, Erdmann J, et al. Genetic determinants of circulating sphingolipid concentrations in European populations. PLoS Genet 2009;5:1-11.
13. Yu H, Zeidan YH, Wu BX, Jenkins RW, Flotte TR, Hannun YA, Virella-Lowell I. Defective acid sphingomyelinase pathway with Pseudomonas aeruginosa infection in cystic fibrosis. Am J Respir Cell Mol Biol 2009;41:367-375.
14. Brodlie M, McKean MC, Johnson GE, Gray J, Fisher AJ, Corris PA, Lordan JL, Ward C. Ceramide is increased in the lower airway epithelium of people with advanced cystic fibrosis lung Disease. Am J Respir Crit Care Med 2010;182:369-375.
15. Dechecchi MC, Nicolis E, Norez C, Bezzerri V, Borgatti M, Mancini I, Rizzotti P, Ribeiro CM, Gambari R, Becq F, et al. Anti-inflammatory effect of miglustat in bronchial epithelial cells. J Cyst Fibros 2008;7:555-565.
16. Platt FM, Neises GR, Dwek RA, Butters TD. N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis. J Biol Chem 1994;269: 8362-8365.
17. Dwek RA, Butters TD, Platt FM, Zitzmann N. Targeting glycosilation as a therapeutic approach. Nat Rev Drug Discov 2002;1:65-75.
18. Mizukami H, Mi Y, Wada R, Kono M, Yamashita T, Liu Y, Werth N, Sandhoff R, Sandhoff K, Proia RL. Systemic inflammation in glucocerebrosidase-deficient mice with minimal glucosylceramide storage. J Clin Invest 2002;109:1215-1221. (Pubitemid 34496599)
19. Jeyakumar M, Thomas R, Elliot-Smith E, van der Spoel AC, d'Azzo A, Hugh Perry V, Butters TD, Dwek RA, Platt FM. Central nervous system inflammation is a hallmark of pathogenesis in mouse models of GM1 and GM2 gangliosidosis. Brain 2003;126:974-987. (Pubitemid 36372994)
20. Schiffmann R, Fitzgibbon EJ, Harris C, DeVile C, Davies EH, Abel L, van Schaik IN, Benko W, Timmons M, Ries M, et al. Randomized, controlled trial of miglustat in Gaucher's disease Type 3. Ann Neurol 2008;64:514-522.
21. Becker KA, Riethmüller J, Lüth A, Döring G, Kleuser B, Gulbins E. Acid sphingomyelinase inhibitors normalize pulmonary ceramide and inflammation in cystic fibrosis. AmJ Respir CellMol Biol 2010;42:716-724.
22. Dechecchi MC, Nicolis E, Mazzi P, Paroni M, Cioffi F, Tamanini A, Bezzerri V, Tebon M, Quiri F, Lampronti I, Mancini I, Borgatti M, Bragonzi A, Gambari R, Scupoli MT, Berton G, Cabrini G. Downmodulation of neutrophil chemotactic signaling by targeting the metabolism of sphingolipids. Pediatr Pulmonol 2010;23 (Suppl):243-244.
23. Zeitlin PL, Lu L, Rhim J, Cutting G, Stetten G, Kieffer KA, Craig R, Guggino WB. A cystic fibrosis bronchial epithelial cell line: immortalization by Adeno-12-SV40 infection. Am J Respir Cell Mol Biol 1991;4:313-319.
24. Zabner J, Karp P, Seiler M. Phillips Sl, Mitchell CJ, Saavedra M, Welsh M, Klingelhutz AJ. Development of cystic fibrosis and non cystic fibrosis airway cell lines. Am J Physiol Lung Cell Mol Physiol 2003;284: L844-L854. (Pubitemid 36459031)
25. Vicentini LP, Mazzi L, Caveggion E, Continolo S, Fumagalli L, Lapinet- Vera JA, Lowell CA, Berton G. FGR deficiency results in defective eosinophil recruitment to the lung during allergic airway inflammation. J Immunol 2002;168:6446.
26. Hurwitz R, Ferlinz K, Vielhaber G, Moczall H, Sandhoff K. Processing of human acid sphingomyelinase in normal and I-cell fibroblasts. J Biol Chem 1994;269:5440-5445. (Pubitemid 24239543)
27. Kornhuber J, Tripal P, Reichel M, Terfloth L, Bleich S, Wiltfang J, Gulbins E. Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model. J Med Chem 2008;51:219-237.
28. Riethmüller J, Anthonysamy J, Serra E, Schwab M, Döring G, Gulbins E. Therapeutic efficacy and safety of amitriptyline in patients with cystic fibrosis. Cell Physiol Biochem 2009;24:65-72.
29. Hanada K. Sphingolipids in infectious diseases. Jpn J Infect Dis 2005;58: 131-148. (Pubitemid 41460590)
30. Heung Lj, Luberto C, Del Poeta M. Role of sphingolipids in microbial pathogenesis. Infect Immun 2006;74:28-39. (Pubitemid 43023055)
31. Yohe HC, Kitzmiller TJ, Bement WJ, Dwyer BE, Sinclair JF. Reduced inflammatory potential of peritoneal macrophages recruited in mice pretreated with a glycolipid synthesis inhibitor. Inflammopharmacology 2006;14:155-160.
32. Treiber A, Morand O, Clozel M. The pharmacokinetics and tissue distribution of the glucosylceramide synthase inhibitor miglustat in the rat. Xenobiotica 2007;37:298-314. (Pubitemid 46439676)
33. Platt FM, Reinkensmeier G, Dwek RA, Butters TD. Extensive glycosphingolipid depletion in the liver and lymphoid organs of mice treated with N-butyldeoxynojirimycin. J Biol Chem 1996;272:19365-19372. (Pubitemid 27337732)
34. Butters TD, Dwek RA, Platt FM. Imino sugar inhibitors for treating the lysosomal glycoshingolipidoses. Glycobiology 2005;15:43R-52R. (Pubitemid 41511483)
35. Walden CM, Sandhoff R, Chuang CC, Yildiz Y, Butters TD, Dwek RA, Platt FM, van der Spoel AC. Accumulation of glucosylceramide in murine testis, caused by inhibition of beta-glucosidase 2: implications for spermatogenesis. J Biol Chem 2007;282:32655-32664. (Pubitemid 350159292)
36. Billet A, Melin P, Jollivet M, Mornon JP, Callebaut I, Becq F. C terminus of nucleotide binding domain 1 contains critical features for cystic fibrosis transmembrane conductance regulator trafficking and activation. J Biol Chem 2010;285:22132-22140.
37. Lubamba B, Lebacq J, Lebecque P, Vanbever R, Leonard A, Wallemacq P, Leal T. Airway delivery of low-dose miglustat normalizes nasal potential difference in F508del cystic fibrosis mice. Am J Respir Crit Care Med 2009;179:1022-1028.
38. Vielhaber G, Brade L, Lindner B, Pfeiffer S, Wepf R, Hintze U, Wittern KP, Brade H. Mouse anti-ceramide antiserum: a specific tool for the detection of endogenous ceramide. Glycobiology 2001;11:451-457. (Pubitemid 32655239)
39. Göggel R, Winoto-Morbach S, Vielhaber G, Imai Y, Lindner K, Brade L, Brade H, Ehlers S, Slutsky AS, Schütze S, et al. PAF-mediated pulmonary edema: a new role for acid sphingomyelinase and ceramide. Nat Med 2004;10:155-160. (Pubitemid 38524885)
40. Wang G, Krishnamurthy K, Chiang Y-W, Dasgupta S, Bieberich E. Regulation of neural progenitor cell motility by ceramide and potential implications for mouse brain development. J Neurochem 2008; 106:718-733.
41. Bielawski J, Szulc ZM, Hannun YA, Bielawska A. Simultaneous quantitative analysis of bioactive sphingolipids by high-performance liquid chromatography-tandem mass spectrometry. Methods 2006;39:82-91. (Pubitemid 44107706)
42. Won JS, Singh I. Sphingolipid signaling and redox regulation. Free Radic Biol Med 2006;40:1875-1888. (Pubitemid 43728861)
43. Won JS, Im YB, Khan M, Singh AK, Singh I. The role of neutral sphingomyelinase produced ceramide in lipopolysaccharide-mediated expression of inducible nitric oxide synthase. J Neurochem 2004;88: 583-593. (Pubitemid 38140203)
44. Maubach KA, Rupniak NM, Kramer MS, Hill RG. Novel strategies for pharmacotherapy of depression. Curr Opin Chem Biol 1999;4: 481-488. (Pubitemid 29376111)
45. Hollak CE, Hughes D, van Schaik IN, Schwierin B, Bembi B. Miglustat (Zavesca) in Type 1 Gaucher disease: 5-year results of a post-authorisation safety surveillance programme. Pharmacoepidemiol Drug Saf 2009; 18:770-777.
46. Yanagi S, Ashitani J, Ishimoto H, Date Y, Mukae H, Chino N, Nakazato M. Isolation of human beta-defensin-4 in lung tissue and its increase in lower respiratory tract infection. Respir Res 2005;6:130.
47. Tecle T, Tripathi S, Hartshorn KL. Defensins and cathelicidins in lung immunity. Innate Immun. 2010;16:151-159.